Sexuality and schizophrenia: A review

Schizophrenia Bulletin

Volumn 30, Issue 4, 2004, Pages 767-779

  Kelly, Deanna L ^a,b   Conley, Robert R ^b,c  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Amenorrhea; Antipsychotics; Prolactin; Schizophrenia; Sexual dysfunction

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BETHANECHOL; BROMOCRIPTINE; CABERGOLINE; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PRASTERONE; PROLACTIN; QUETIAPINE; RISPERIDONE; SILDENAFIL; TESTOSTERONE; YOHIMBINE; ZIPRASIDONE;

AMENORRHEA; ANORGASMIA; DISEASE EXACERBATION; EJACULATION DISORDER; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPOTENSION; IMPOTENCE; LIBIDO DISORDER; MENORRHAGIA; NAUSEA; ORGASM DISORDER; PATIENT CARE; PRIAPISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SOCIAL PSYCHOLOGY; VAGINAL DRYNESS;

EID: 16344388219     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007130     Document Type: Review

References (142)

1. Aizenberg, D.; Modai, I.; Landa, A.; Gil-Ad, I; and Weizman, A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Journal of Clinical Psychiatry, 62:541-544, 2001.
2. Aizenberg, D.; Zemishlany, Z.; Dorfman-Etrog, P.; and Weizman, A. Sexual dysfunction in male schizophrenic patients. Journal of Clinical Psychiatry, 56:137-141, 1995.
3. Akhtar, S., and Thomson, J.A., Jr. Schizophrenia and sexuality: A review and a report of twelve unusual cases. II. Journal of Clinical Psychiatry, 41:166-174, 1980.
4. Ananth, J.; Burgoyne, K.; Smith, M.; and Gadasalli, R. "Prolactin Levels and New Antipsychotics." Paper presented at the 21st Annual Congress, European College of Neuropsychopharmacology, Glasgow, Scotland, July, 1998.
5. Arvanitis, L.A., and Miller, B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry, 42(4):233-246, 1997.
6. Ashton, A.K., and Bennett, R.G. Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. [Letter]. Journal of Clinical Psychiatry, 60:194-195, 1999.
7. AstraZeneca Pharmaceuticals. "Seroquel (Quetiapine Fumarate) Tablets." Product monograph. Wilmington, DE: AstraZeneca, 2001.
8. Balogh, S.; Hendricks, S.E.; and Kang, J. Treatment of fluoxetine-induced anorgasmia with amantadine. [Letter]. Journal of Clinical Psychiatry, 53:212-213, 1992.
9. Baptista, T.; Reyes, D.; and Hernandez, L. Antipsychotic drugs and reproductive hormones: Relationship to body weight regulation. Pharmacology, Biochemistry, and Behavior, 62:409-417, 1999.
10. Barnes, T.R.E., and Harvey, C.A. Psychiatric drugs and sexuality. In: Riley, A.J.; Peet, M; and Wilson, C., eds. Sexual Pharmacology. Oxford, U.K.: Oxford University Press, 1993. pp. 176-196.
11. Benatov, R.; Reznik, I.; and Zemishlany, Z. Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient. European Psychiatry, 14:353-355, 1999.
12. Benazzi, F. Gynecomastia with risperidone-fluoxetine combination. [Abstract]. Pharmacopsychiatry, 32:41, 1999.
13. Bengtsson-Tops, A., and Hansson, L. Clinical and social needs of schizophrenic outpatients living in the community: The relationship between needs and subjective quality of life. Social Psychiatry and Psychiatric Epidemiology, 34(10):513-518, 1999.
14. Bobes, J.; Garc A-Portilla, M.P.; Rejas, J.; Hern Ndez, G.; Garcia-Garcia, M.; Rico-Villademoros, F.; and Porras, A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. Journal of Sex and Marital Therapy, 29:125-147, 2003.
15. Bobes, J.; Gutierrex, M.; Gilbert, J.; Gonzalez, M.P.; and Herraiz, M.L. Quality of life and disability in chronic schizophrenics treated with risperidone and previously treated with depot neuroleptics. Actas Espanolas de Psiquiatria, 27(4):229-234, 1999.
16. Borison, R.L.; Arvanitis, L.A.; and Miller, B.G. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. Journal of Clinical Psychopharmacology, 16(2):158-169, 1996.
17. Bristol-Myers Squibb Company. "Abilify (Aripiprazole) Tablets." Product monograph. Princeton, DE: Bristol-Myers Squibb, 2002.
18. Buddeberg, C.; Furrer, H.; and Limacher, B. Sexual problems in schizophrenic patients treated by ambulatory care. Psychiatrische Praxis, 15(6):187-191, 1988.
19. Burke, M.; McEvoy, J.P.; and Ritchie, J.C. A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biological Psychiatry, 35:32-35, 1994.
20. Burns, T.; Fioritti, A.; Holloway, F.; Malm, U.; and Rossler, W. Case management and assertive community treatment in Europe. Psychiatric Services, 52(5):631-636, 2001.
21. Casey, D.E.; Carson, W.H.; Saha, A.R.; Liebeskind, A.; Ali, M.W.; Jody, D.; Ingenito, G.G.; and Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology, 166:391-399, 2003.
22. Clayton, A.H. Recognition and assessment of sexual dysfunction associated with depression. Journal of Clinical Psychiatry, 62(Suppl 3):5-9, 2001.
23. Clayton, A.H.; McGarvey, E.L.; and Clavet, G.J. The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacology Bulletin, 33(4):731-745, 1997.
24. Clayton, A.H.; Owens, J.E.; and McGarvey, E.L. Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacology Bulletin, 31:397-413, 1995.
25. Cohen, L.G., and Biederman, J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. Journal of Child and Adolescent Psychopharmacology, 11:435-440, 2001.
26. Cohn, J.B.; Brust, J.; DiSerio, F.; and Singer, J. Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Pharmacopsychiatry, 13:173-179, 1985.
27. Compton, M.T., and Miller, A.H. Priapism associated with conventional and atypical antipsychotic medications: A review. Journal of Clinical Psychiatry, 62(5):362-366, 2001.
28. Conley, R.R., and Kelly, D.L. Pharmacological treatment of schizophrenia. Caddo, OK: Professional Communications, 2000.
29. Conley, R.R., and Mahmoud, R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 158(5):765-774, 2001.
30. Cournos, F.; Guido, J.R.; Coomaraswamy, S.; Meyer-Bahlburg, H.; and Sugden, R. Sexual activity and risk of HIV infection among patients with schizophrenia. American Journal of Psychiatry, 151:228-232, 1994.
31. Crawford, A.M.; Beasley, C.M., Jr.; and Tollefson, G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26:41-54, 1997.
32. Degen, K. Sexual dysfunction in women using major tranquilizers. Psychosomatics, 23:959-961, 1982.
33. Derogatis, L.R. The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): An introductory report. Journal of Sex and Marital Therapy, 23:291-304, 1997.
34. Dickson, R.A.; Dalby, J.T.; Williams, R.; and Edwards, A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. [Letter]. American Journal of Psychiatry, 152:1102-1103, 1995.
35. Dickson, R.A., and Edwards, A. Clozapine and fertility. American Journal of Psychiatry 154:582-583, 1997.
36. Dickson, R.A., and Glazer, W.M. Hyperprolactinemia and male sexual dysfunction. [Letter]. Journal of Clinical Psychiatry, 60:125, 1999.
37. Dickson, R.A.; Glazer, W.M.; and Violato, C. A computerized self-report questionnaire for assessing sexual functioning in psychotic patients: The DGSF scale. Schizophrenia Research, 49:283, 2001.
38. Dickson, R.A., and Hogg, L. Pregnancy of a patient treated with clozapine. Psychiatric Services, 49:1081-1083, 1988.
39. Eli Lilly and Company. "Zyprexa (Olanzapine) Tablets." Product monograph. Indianapolis, IN: Eli Lilly, 2001.
40. Emes, C.E., and Millson, R.C. Risperidone-induced priapism. [Letter]. Canadian Journal of Psychiatry, 39(5):315-316, 1994.
41. Faiman, C. Endocrine causes of impotence. Cleveland Clinic Journal of Medicine, 60:428-429, 1993.
42. Fava, M.; Rankin, M.A.; Alpert, J.E.; Nierenberg, A.A.; and Worthington, J.J. An open trial of oral sildenafil in antidepressant induced sexual dysfunction. Psychotherapy and Psychosomatics, 67:328-331, 1998.
43. Fleischhacker, W.W.; Meise, U.; Gunther, V.; and Kurz, M. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatrica Scandinavica, 89(Suppl 382):11-15, 1994.
44. Friedman, G., and Harrison, G. Sexual histories, attitudes, and behavior of schizophrenic and "normal" women. Archives of Sexual Behavior, 13:555-567, 1984.
45. Gazzola, L.R., and Opler, L.A. Return of menstruation after switching from risperidone to olanzapine. [Letter]. Journal of Clinical Psychopharmacology, 18:486-487, 1998.
46. Gelenberg, A.J.; McGahuey, C.; Laukes, C.; Okayli, G; Moreno, F.; and Zentner, L. Mirtazapine substitution in SSRI-induced sexual dysfunction. Journal of Clinical Psychiatry, 61:356-360, 2000.
47. Ghadirian, A.M.; Chouinard, G.; and Annable, L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Journal of Nervous and Mental Disease, 170(8):463-467, 1982.
48. Gil-Ad, I.; Dickerman, Z.; Weizman, R.; Weizman, A.; Tyano, S.; and Laron, Z. Abnormal growth and hormone response to LRH and TRH in adolescent schizophrenic boys. American Journal of Psychiatry, 138:357-360, 1981.
49. Goldstein, J.M., and Cantillon, M. "Low incidence of reproductive/hormonal side effects with Seroquel (quetiapine) is supported by its lack of elevation of plasma prolactin concentrations." Paper presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 1997.
50. Gottesman, I.I., and Groome, C.S. HIV/AIDS risks as a consequence of schizophrenia. Schizophrenia Bulletin, 23(4):675-684, 1997.
51. Gupta, S.; Frank, B.; and Madhusoodanan, S. Risperidone-associated galactorrhea in a male teenager. [Letter]. Journal of the American Academy of Child and Adolescent Psychiatry, 40(5):504-505, 2001.
52. Hafner, H.; Riecher-Rossler, A.; An Der Heiden, W.; Maurer, K.; Fatkenheuer, B.; and Loffler, W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychological Medicine, 23:925-940, 1993.
53. Harden, C.L. Treatment of sexual disorders in people with epilepsy. Epilepsy and Behavior, 5S:38-41, 2002.
54. Harris, D.S.; Wolkowitz, O.M.; and Reus, V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World Journal of Biological Psychiatry, 2:99-102, 2001.
55. Hummer, M.; Kemmler, G.; Kurz, M.; Kurzthaler, I.; Oberbauer, H.; and Fleischhacker, W.W. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. American Journal of Psychiatry, 156(4):631-633, 1999.
56. Janssen Pharmaceutica. "Risperdal (Risperidone) Tablets/Oral Solution." Product monograph, Titusville, NJ, 2000.
57. Kane, J.M.; Carson, W.H.; Saha, A.R.; McQuade, R.D.; Ingenito, G.G.; Zimbroff, D.L.; and Ali, M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry, 63:763-771, 2002.
58. Kaneda, Y. Risperidone-induced ejaculatory dysfunction: A case report. European Psychiatry, 16(2):134-135, 2001.
59. Keitner, G.I., and Selub, S. Spontaneous ejaculations and neuroleptics. Journal of Clinical Psychopharmacology, 3:34-36, 1983.
60. Kelly, D.L., and Conley, R.R. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophrenia Research, 63:195-196, 2003.
61. Kim, K.S.; Pae, C.U.; Chae, J.H.; Bahk, W.M.; Jun, T.Y.; Kim, D.J.; and Dickson, R.A. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Journal of Clinical Psychiatry, 63:408-413, 2002.
62. Kim, Y.K.; Kim, L.; and Lee, M.S. Risperidone and associated amenorrhea: A report of 5 cases. Journal of Clinical Psychiatry, 60:315-317, 1999.
63. King, D.J.; Link, C.G.; and Kowalcyk, B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology, 137:139-146, 1998.
64. Kleinberg, D.L.; Davis, J.M.; de Coster, R.; Van Baelen, B.; and Brecher, M. Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology, 19:57-61, 1999.
65. Kockott, G., and Pfeiffer, W. Sexual disorders in nonacute psychiatric outpatients. Comprehensive Psychiatry, 37:56-61, 1996.
66. Lare, S.B., and Labbate, L.A. Sildenafil and erectile dysfunction. [Letter]. American Journal of Psychiatry, 157:2055-2056, 2000.
67. Lewis, J., and Scott, E. The sexual education needs of those disabled by mental illness. Psychiatric Rehabilitation Journal, 21:164-167, 1997.
68. Lukoff, D.; Gioia-Hasick, D.; Sullivan, G.; Golden, J.S, and Nuechterlein, K.H. Sex education and rehabilitation with schizophrenic male outpatients. Schizophrenia Bulletin, 12(4):669-677, 1986.
69. Mabini, R.; Wergowske, G.; and Baker, F.M. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatric Services, 51:983-985, 2000.
70. Macdonald, S.; Halliday, J.; MacEwan, T.; Sharkey, V.; Farrington, S.; Wall, S.; and McCreadie, R.G. Nithsdale Schizophrenia Surveys 24: Sexual dysfunction. Case-control study. British Journal of Psychiatry, 182:50-56, 2003.
71. Markianos, M.; Hatzimanolis, J.; and Lykouras, L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. European Archives of Psychiatry and Clinical Neuroscience, 251(3):141-146, 2001.
72. Matthews, S.C, and Dimsdale, J.E. Priapism after a suicide attempt by ingestion of olanzapine and gabapentin. [Letter]. Psychosomatics, 42(3):280-281, 2001.
73. McCann, E. The expression of sexuality in people with psychosis: Breaking the taboos. Journal of Advanced Nursing, 32(1):132-138, 2000.
74. McConaghy, N. Unresolved issues in scientific sexology. Archives of Sexual Behavior, 28:285-318, 1999.
75. McGahuey, C.A.; Gelenberg, A.J.; Laukes, C.A.; Moreno, F.A.; Delgado, P.L.; McKnight, K.M.; and Manber, R. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. Journal of Sex and Marital Therapy, 26:25-40, 2000.
76. Meston, C.M., and Gorzalka, B.B. Psychoactive drugs and human sexual behavior: The role of serotonergic activity. Journal of Psychoactive Drugs, 24:1-40, 1992.
77. Miller, L.J. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophrenia Bulletin, 23(4):623-635, 1997.
78. Miller, L.J., and Finnerty, M. Sexuality, pregnancy, and childrearing among women with schizophrenia-spectrum disorders. Psychiatric Services, 47:502-506, 1996.
79. Moloney, P.; Elliot, G.B.; and Johnson, H.W. Experiences with priapism. Journal of Urology, 116:51-53, 1975.
80. Mullen, B.; Brar, J.S.; Vagnucci, A.H.; and Gangulu, R. Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine, or risperidone. Schizophrenia Research, 48:155-158, 2001.
81. Munarriz, R.; Talakoub, L.; Flaherty, E.; Gioia, M.; Hoag, L.; Kim, N.N.; Traish, A., Goldstein, I.; Guay, A.; and Spark, R. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: Androgen and questionnaire results. Journal of Sex and Marital Therapy, 28:165-173, 2002.
82. Neumann, N.U., and Frasch, K. Olanzapine and pregnancy: 2 case reports. Der Nervenarzt, 72:876-878, 2001.
83. Nicolson, R, and McCurley, R. Risperidone-associated priapism. [Letter]. Journal of Clinical Psychopharmacology, 17(2):133-134, 1997.
84. Novartis Pharamceuticals. "Clozaril (Clozapine) Tablets." Product monograph. East Hanover, NJ: Novartis, 2002.
85. Nurnberg, H.G.; Hensley, P.L.; Lauriello, J.; Parker, L.M.; and Keith, S.J. Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatric Services, 50:1076-1078, 1999a.
86. Nurnberg, H.G.; Lauriello, J.; Hensley, P.L.; Parker, L.M.; and Keith, S.J. Sildenafil for iatrogenic serotonergic anti-depressant medication-induced sexual dysfunction in 4 patients. Journal of Clinical Psychiatry, 60:33-35, 1999b.
87. Oades, R.D., and Schepker, R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology, 19:373-385, 1994.
88. Othmer, E., and Othmer, S.C. Evaluation of sexual dysfunction. Journal of Clinical Psychiatry, 48:191-193, 1987.
89. Otto-Salaj, L.L., and Stevenson, L.Y. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. AIDS Reader, 11:197-204, 2001.
90. Pais, V.M., and Ayvazian, P.J. Priapism from quetiapine overdose: First report and proposal of mechanism. [Abstract]. Urology, 58(3):462, 2001.
91. Peacock, L.; Solgard, T.; Lublin, H.; and Gerlach, J. Clozapine versus typical antipsychotics: Effects and side effects. Neuropsychopharmacology, 10:223-354, 1994.
92. Perkins, D.O. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63:1121-1128, 2002.
93. Pfizer, Inc. "GEODON (Ziprasidone HCI)." Product monograph. New York, NY: Pfizer, 2001.
94. Pinderhughes, C.A.; Grace, E.B.; and Reyna, L.J. Psychiatric disorders and sexual functioning. American Journal of Psychiatry, 128:1276-1283, 1972.
95. Pollack, M.H.; Reiter, S.; and Hammerness, P. Genitourinary and sexual adverse effects of psychotropic medication. International Journal of Psychiatry in Medicine, 22:305-327, 1992.
96. Pollack, M.H., and Rosenbaum, J.F. Management of anti-depressant-induced side effects: A practical guide for the clinician. Journal of Clinical Psychiatry, 48:3-8, 1987.
97. Raboch, J. The sexual development and life of female schizophrenic patients. Archives of Sexual Behavior, 13:341-349, 1984.
98. Raja, M. Risperidone-induced absence of ejaculation. International Clinical Psychopharmacology, 14(5):317-319, 1999.
99. Reeves, R.R., and Kimble, R. Prolonged erections associated with ziprasidone treatment: A case report. Journal of Clinical Psychiatry, 64:97-98, 2003.
100. Reeves, R.R., and Mack, J.E. Priapism associated with two atypical antipsychotic agents. Pharmacotherapy, 22:1070-1073, 2002.
101. Reid, K.; Surridge, D.H.; Morales, A.; Condra, M.; Harris, C.; Owen, J.; and Fenemore, J. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet, 2:421-423, 1987.
102. Reiter, W.J.; Pycha, A.; Schatzl, G.; Klingler, H.C.; Mark, I.; Auterith, A.; and Marberger, M. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology, 55;755-758, 2000.
103. Reiter, W.J.; Schatzl, G.; Mark, I.; Zeiner, A.; Pycha, A.; and Marberger, M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urological Research, 29:278-281, 2001.
104. Richelson, E., and Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sciences, 68(1):29-39, 2000.
105. Riecher-Rossler, A. Oestrogen effects in schizophrenia and their potential therapeutic implications - Review. Archives of Women's Mental Health, 5:111-118, 2002.
106. Riecher-Rossler, A., and Hafner, H. Schizophrenia and oestrogens - Is there an association? European Archives of Psychiatry and Clinical Neuroscience, 242:323-328, 1993.
107. Rowlands, P. Schizophrenia and sexuality. Sexual and Marital Therapy, 10:47-61, 1995.
108. Rozan, G.H.; Tuchin, T.; and Kurland, M.L. Some implications of sexual activity for mental illness. Mental Hygiene, 55:318-323, 1971.
109. Rubin, R.T. Prolactin and schizophrenia. In: Meltzer, H.Y., ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press, 1987. pp. 803-808.
110. Sabuncu, T.; Arikan, E.; Tasan, E.; and Hatemi, H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Internal Medicine, 40:857-861, 2001.
111. Sadow, D., and Corman, A. Teaching a human sexuality course to psychiatric patients: The process, pitfalls and rewards. Sexuality and Disability, 6:47-53, 1983.
112. Schiavi, R.C.; Stimmel, B.B.; Mandeli, J.; Schreiner-Engel, P.; and Ghizzani, A. Diabetes, psychological function and male sexuality. Journal of Psychosomatic Research, 39:305-314, 1995.
113. Segraves, R.T. Effects of psychotropic drugs on human erection and ejaculation. Archives of General Psychiatry, 46:275-284, 1989.
114. Shader, R.I., and DiMascio, A. Endocrine effects of psychotropic drugs: VI. Male sexual function. Connecticut Medicine, 32:847-848, 1968.
115. Shen, W.W., and Park, S. Thioridazine-induced inhibition of female orgasm. Psychiatric Journal of the University of Ottawa, 7:249-251, 1982.
116. Shiwach, R.S., and Carmody, T.J. Prolactogenic effects of risperidone in male patients: A preliminary study. Acta Psychiatrica Scandinavica, 98:81-83, 1998.
117. Simons, J.S., and Carey, M.P. Prevalence of sexual dysfunctions: Results from a decade of research. Archives of Sexual Behavior, 30:177-219, 2001.
118. Small, J.G.; Hirsch, S.R.; Arvanitis, L.A.; Miller, B.G.; and Link, C.G. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Archives of General Psychiatry, 54(6):549-557, 1997.
119. Smith, S.M.; O'Keane, V.; and Murray, R. Sexual dysfunction in patients taking conventional antipsychotic medication. British Journal of Psychiatry, 181:49-55, 2002.
120. Sovner, R. Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. [Letter]. Journal of Clinical Psychiatry, 4:169, 1984.
121. Stevens, J.R. Schizophrenia: Reproductive hormones and the brain. American Journal of Psychiatry, 159:713-719, 2002.
122. Sullivan, G., and Lukoff, D. Sexual side effects of antipsychotic mediation: Evaluation and interventions. Hospital and Community Psychiatry, 41:1238-1241, 1990.
123. Tamminga, C.A.; Mack, R.J.; Granneman, G.R.; Silber, C.J.; and Kashkin, K.B. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. International Clinical Psychopharmacology, 12(Suppl 1):S29-S35, 1997.
124. Tenyi, T.; Trixler, M.; and Keresztes, Z. Quetiapine and pregnancy. [Letter]. American Journal of Psychiatry, 159:674, 2002.
125. Teusch, L.; Scherbaum, N.; Bohme, H.; Bender, S.; Eschmann-Mehl, G.; and Gastpar M. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment: Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry, 28:84-92, 1995.
126. Tollin, S.R. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. Journal of Endocrinological Investigation, 23:765-770, 2000.
127. Tran, P.V.; Hamilton, S.H.; Kuntz, A.J.; Potvin, J.H.; Anderson, S.W.; Beasley, C., Jr.; and Tollefson, G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17:407-418, 1997.
128. Tsai, S.J., and Hong, C.J. Haloperidol-induced impotence improved by switching to olanzapine. [Letter]. General Hospital Psychiatry, 22:391-392, 2000.
129. Turrone, P.; Kapur, S.; Seeman, M.V.; and Flint, A.J. Elevation of prolactin levels by atypical antipsychotics. American Journal of Psychiatry, 159:133-135, 2002.
130. Van Cauter, E.; Linkowski, P.; Kerkhofs, M.; Hubain, P.; L'Hermite-Baleriaux, M.; Leclercq, R.; Brasseur, M.; Copinschi, G.; and Mendlewicz, J. Circadian and sleep-related endocrine rhythms in schizophrenia. Archives of General Psychiatry, 48:348-356, 1991.
131. Veldhuis, J.D. Neuroendocrine mechanisms mediating awakening of the human gonadotropic axis in puberty. Pediatric Nephrology, 10:304-317, 1996.
132. Von Krafft-Ebing, R. Text-Book of Insanity: Based on Clinical Observations for Practitioners and Students in Medicine. Philadelphia, PA: F.A. Davis, 1905.
133. Wasow, M. Sexuality and the institutionalized mentally ill. Sexuality and Disability, 3:3-15, 1980.
134. Wilson, C.A. Pharmacological targets for the control of male and female sexual behaviour. In: Riley, A.J.; Peet, M.; and Wilson, C., eds. Sexual Pharmacology. Oxford, U.K.: Oxford University Press, 1993. pp. 1-58.
135. Wirshing, D.A.; Pierre, J.M.; Marder, S.R.; Saunders, C.S.; and Wirshing, W.C. Sexual side effects of novel antipsychotic medications. Schizophrenia Research, 56:25-30, 2002.
136. Withersty, D.J. Sexual attitudes of hospital personnel: A model for continuing education. American Journal of Psychiatry, 133:573-575, 1976.
137. Wolfe, S.D., and Menninger, W.W. Fostering open communication about sexual concerns in a mental hospital. Hospital and Community Psychiatry, 24:147-150, 1973.
138. Yamada, K.; Kanba, S.; Yagi, G.; and Asai, M. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. [Letter]. Journal of Clinical Psychopharmacology, 17:234-235, 1997.
139. Yamada, K.; Kanba, S.; Yagi, G.; and Asai, M. Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. [Letter]. Journal of Clinical Psychopharmacology, 19:380-381, 1999.
140. Yassa, R., and Lal, S. Impaired sexual intercourse as a complication of tardive dyskinesia. [Letter]. American Journal of Psychiatry, 142:1514-1515, 1985.
141. Zajecka, J.; Mitchell, S.; and Fawcett, J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacology Bulletin, 33:755-760, 1997.
142. Zajecka, J.M.; Rao, D.; and Skubiak, T. "Psychometric Analyses of the Rush Sexual Inventory." Presented at the 40th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 30-June 2, 2000.